



A Unique & Global Healthcare Testing Company



FY2007 3Q Business Results

February, 5 2008
SYSMEX CORPORATION

Topics - 1



Alliances

- Alliance Formed with IDEXX; World's Largest Animal Diagnostic Testing Company
 - ✓ IDEXX to place Sysmex products into its reference laboratories
 - ✓ The two companies to explore some ways to leverage their strengths

>About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. is a worldwide leader in the development and commercialization of innovative technology-based products and services for veterinary, food and water applications. Headquartered in southern Maine, IDEXX conducts operations through more than 60 locations around the world, and employs over 4,500 people in full-and part-time positions.

- Announcement of Sysmex and bioMérieux Form a Commercial Joint Venture for the Japanese In Vitro Diagnostics Market(Sysmex will take a 34% equity stake in bioMérieux Japan, Ltd.
 - ✓ From April 2008, the sales and customer service activities will be contracted out from the JV to Sysmex.

>About bioMérieux

Advancing Diagnostics to Improve Public Health A world leader in the field of in vitro diagnostics for over 40 years, bioMérieux is present in more than 150 countries through 36 subsidiaries and a large network of distributors. In 2006, revenues reached €1.037 billion with 83% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on Euronext Paris.

- Distribution agreement with McKesson Medical-Surgical(US)
 - ✓ Setup for sales in the US Physicians Office Laboratories market

Affiliates and offices

- Established Sysmex Canada Inc.
 - ✓ From January 2008, the newly established Sysmex Canada will provide direct sales and support of Sysmex products

Topics - 2

New products/Technologies

- Released HISCL-2000i, a fully automated immunoassay analyzer enabling highly sensitive and high-speed assay
 - ✓ Examine the presence or absence of infectious diseases, cancer, heart ailments, and autoimmune diseases
 - ✓ Widening product line-up of reagents
- Received FDA Approval for Automated hematology analyzer XE-5000
 - ✓ Startup of marketing for the automated hematology analyzer XE-5000
- Won Awards in 2007 Kinki Local Commendation for Invention
 - ✓ Shibuso-award for one invention and Invention Incentive

High sensitivity • Speedy •
Minimal sample volume



Automated hematology analyzer
HISCL-2000i



Automated hematology analyzer *XE-5000*


Other developments

- Received two awards including "Special prize" in the Nikkei Annual Report Award 2007
- Mizuki Noguchi won the Tokyo International Women's Marathon


Annual Report



(She belongs to Sysmex Women's truck & Field Team)



Financial Highlights





Geographic Segment Information (Americas & Europe)

【 Americas 】

- Favorable trend in sales to blood centers
- Extensive orders from integrated healthcare networks
- Slow sales of urinalysis analyzers and coagulation analyzers
- Established Sysmex Canada Inc.
- Distribution agreement with McKesson Medical-Surgical
- Receive FDA approval for the automated hematology analyzer XE-5000
- Startup of the reagent production plant in Chicago

*POL ; Physicians Office Laboratories



【 Europe 】


- Adverse market condition due to the impact of medical service reform in advanced area
- Sales increase in Central Europe due to direct-sales impact
 - ✓ SG&A increase (labor cost, goodwill depreciation and so on)
- Brisk sales of hematology analyzers in the Mideast and Africa
 - ✓ Successful bids for big contracts under the government initiative
- Slow sales of coagulation analyzers
- Brisk sales of urinalysis analyzers

Geographic Segment Information (China & AP)




【China】

- Extensive orders for systems in the hematology segment
- Cost pressure due to reduction of test expenses (insurance points)
- Increase bids of middle and low-end hematology analyzers under the government initiative analyzers
 - ✓ Decrease in the rate of successful bidding in tenders along with rise of indigenous manufacturers
- Increase in highly-functional hematology analyzers
 - ✓ Brisk sales of high unit-cost reagent sales
- Increase in contracts for replacement/upgrading in the coagulation segment
 - ✓ Increase in reagents
- Brisk sales of urinalysis analyzers



(Net Sales to Outside customers)

AP



(Operating Income)

【AP】


- Launch of sales activities in Menggu
 - ✓ Startup of sales activities by distributor
- Successful bids for big contracts under Malaysia's government initiative
- Beginning of direct sales and support in Thailand
- Influence by delayed marketing of new products
 - ✓ In the segments of coagulation and clinical chemistry
- Startup of the reagent production plant in Baddi (India)

Geographic Segment Information (Japan)



【Japan】

- Cost pressures from medical institutions whose management faces harsh circumstances
- Accelerated reorganization of the industry including manufacturers, distributors, and commercial labs
- Deployment of low-price strategies by competitors
- Successful bids for big contracts of university hospitals
- Influence by delayed marketing of new products
 - ✓ Delayed debut of new products in the segments of immunochemistry and coagulation
- Startup of marketing of the automated hematology analyzer XE-5000
- Favorable trend of sales of the UF-1000i series of urinalysis analyzers
 - ✓ Increased recognition of utility based on the guidelines for the diagnosis of hematuria
- Slow sales of influenza testing kits
 - ✓ Reinforcement of sales promotion activities for influenza testing kits for the flu season

Urine cell analyzer *UF-1000i*influenza testing kits *POCTEM S Influenza*

FY2007 Consolidated Earnings Forecast


FY2007 Consolidated Earnings Forecast (Announced in May 2007)

- Sales: ¥112 billion
- Ordinary Income: ¥15.3 billion
- Income: ¥ 9.8 billion
- Ordinary Income ratio: ¥13.7%
- Income ratio: 8.8%

Investment plan

➤ Equipment: ¥8.3 billion

➤ R&D: 9.8 billion



Projected Dividend for FY2007



	Interim dividend	Year-end dividend	Total	Dividends ratio (Consolidate)
FY2007	¥ 20	¥ 20	¥ 40	20. 8%
FY2006	¥ 16	¥ 20	¥ 36	20. 0%

(Announced in May 2007)



Forward-looking Statements

This material contains forward-looking statements about Sysmex Corporation and its group companies (the Sysmex Group). These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it, and involve both known and unknown risks, uncertainties and other factors, including but not limited to: global economic conditions, competitive situations, and changes in exchange rates. Such risks, uncertainties, and other factors may cause the actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements, or financial position expressed or implied within these forward-looking statements.

Challenging the Frontiers of Healthcare Testing

SYSMEX CORPORATION

<Contact>
IR & Corporate Communication Div.
Phone: 81-078-265-0500
Email: info@sysmex.co.jp
URL: www.sysmex.co.jp

END